Full results from a phase 3 trial published in The Lancet show that an experimental once-daily pill cut the risk of pulmonary arterial hypertension getting worse by 55% compared with placebo, in patients already taking standard treatment.
The most important sentence for patients comes next. Ralinepag is not approved by the FDA, cannot be prescribed, and its maker says it plans to submit an application for approval sometime in the second half of this year.
The ADVANCE OUTCOMES trial randomly assigned 687 adults with PAH to ralinepag or placebo on top of their existing therapy, and followed them until a set number of worsening events occurred. Among those on ralinepag, 64 of 350 patients (18%) had a first clinical worsening event, compared with 121 of 337 (36%) on placebo. The hazard ratio was 0.45, with a 95% confidence interval of 0.33 to 0.62 and a p value below 0.0001.
What a Clinical Worsening Endpoint Actually Counts
Composite endpoints get reported as single numbers, which hides what patients experienced.
Clinical worsening in this trial was an adjudicated combination of events that mark PAH progression: death, hospitalization because the disease deteriorated, and other evidence of progression such as declining exercise capacity or the need to add treatment. A patient counted once, at their first event.
That construction matters for interpretation. A 55% reduction in a composite does not mean a 55% reduction in deaths. It means fewer patients crossed the first of several thresholds, and the individual components carry very different weight to a person living with the disease. Anyone reading this should look for the component breakdown in the full paper rather than assume the headline figure applies to mortality.
The absolute numbers are worth holding alongside the relative ones. Eighteen percent versus 36% is an 18 percentage point difference, which in a rare progressive disease is a substantial result rather than a marginal one. Both framings are accurate, and reporting only the 55% would overstate what a single patient can expect.
Secondary endpoints also favored ralinepag, including improved six-minute walk distance, a 24.3% reduction in the cardiac stress marker NT-proBNP, and higher odds of clinical improvement.
The Trade-Off the Headline Omits
The Lancet's own conclusion contains a qualification that most coverage will drop.
The authors wrote that ralinepag "significantly reduced the risk of first clinical worsening compared with placebo," and then added that it was associated with more treatment discontinuations related to adverse events than placebo. That is not a footnote. Prostacyclin pathway drugs are effective in PAH and are also known for tolerability problems, and the ability to stay on a medication is part of whether it works in practice.
The paper's introduction makes the same point about the existing class, noting that use of prostacyclin therapies can be limited by route of administration, dosing frequency, titration requirements, and tolerability. A once daily oral option addresses the first three. Whether it solves the fourth is exactly what the discontinuation signal speaks to, and readers deserve the number and the specific side effects from the full text.
The trial was funded by United Therapeutics, which developed the drug. That does not invalidate a randomized, double blind, placebo-controlled trial published in a major journal, and the design is the strongest available. It does mean the framing in company materials, which describes the results as exceptional and as potentially redefining PAH treatment, is promotional language rather than a scientific characterization.
What PAH Progression Looks Like
Context helps explain why an 18-point difference matters here.
Pulmonary arterial hypertension is a rare disease in which the arteries carrying blood from the heart to the lungs narrow and stiffen. Pressure in the lung circulation rises, and the right side of the heart strains against it. Untreated, that strain leads to right ventricular failure and early death.
Symptoms are unglamorous and easy to attribute to something else: breathlessness on exertion, fatigue, dizziness, chest discomfort, swelling in the legs and abdomen, and eventually breathlessness at rest. Because these overlap with asthma, deconditioning and heart failure, diagnosis is frequently late. Treatment has improved substantially over three decades, and the paper is clear that long-term survival remains poor.
The trial population reflects modern practice rather than untreated disease. Eighty percent of participants were already on two background therapies, and 70% were in the milder of the two functional classes that dominate PAH trials. So this tested whether adding ralinepag helps people already receiving contemporary care, which is the clinically relevant question.
What This Means for Patients Now
For someone living with PAH, the practical answer is that nothing changes today.
Ralinepag cannot be obtained outside a clinical trial. There is no expanded access program described in these materials, no approval date, and no way to know whether the FDA will approve it or on what terms. Patients interested in prostacyclin pathway options should discuss the currently approved ones with their PAH specialist, and can ask whether any open trials fit their situation.
Nobody should change or stop a PAH medication based on trial results for an unapproved drug. PAH regimens are built carefully, and interruptions carry real risk.
What is reasonable now is a conversation at the next specialist visit about whether current therapy is achieving treatment goals, since the premise of this trial was that many patients on dual therapy still progress. That conversation is worth having regardless of what happens to this particular drug.
What Happens Next
United Therapeutics has said it intends to file a New Drug Application with the FDA in the second half of 2026. A standard review would put any decision well into next year, and the agency can request more data.
What remains unknown is the component breakdown of the composite endpoint, the specific adverse events driving discontinuations, how ralinepag compares with existing prostacyclin therapies since the trial used placebo rather than an active comparator, and whether the benefit persists beyond the trial period. MedicalDaily will monitor the FDA submission.
The bottom line: a Lancet-published phase 3 trial found ralinepag reduced first clinical worsening events in PAH from 36% to 18% versus placebo, alongside more discontinuations for side effects. Patients with PAH already on combination therapy are the group this concerns. The reasonable step is a conversation with a PAH specialist about current treatment goals, not an attempt to obtain an unapproved drug. The central uncertainty is whether and when the FDA approves it.
Frequently Asked Questions
What did the trial find? Ralinepag reduced the risk of a first clinical worsening event by 55% versus placebo. In absolute terms, 18% of ralinepag patients had an event compared with 36% on placebo.
Can I get ralinepag? No. It is investigational and not approved by the FDA. United Therapeutics says it plans to file for approval in the second half of 2026.
Does a 55% reduction mean 55% fewer deaths? No. Clinical worsening was a composite of death, hospitalization for worsening disease, and other progression measures. The components are not equivalent.
Were there downsides? Yes. The Lancet reported more treatment discontinuations related to adverse events on ralinepag than on placebo.
Who funded the trial? United Therapeutics, which developed the drug. The trial was randomized, double-blind, and placebo-controlled.
What is PAH? A rare progressive disease in which lung arteries narrow and stiffen, raising pressure and straining the right side of the heart. Symptoms include breathlessness, fatigue, dizziness, and swelling.
Should I change my PAH treatment? No. Do not alter any PAH medication based on results for an unapproved drug. Discuss treatment goals with your specialist.
